Paul Shapiro, PhD, and Jeffrey Hasday, MD, are developing a class of drugs that may be able to reset the natural balance of inflammation and prevent a number of serious diseases.

Allan Doctor, MD, of the School of Medicine and Joga Gobburu, PhD, MBA, of the School of Pharmacy are optimistic they are on the cusp of developing the world’s first viable artificial blood.